Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user shared their 5-month hair progress using oral finasteride and minoxidil, reporting positive results with minimal side effects. They use a chewable 2-in-1 product from Hims for convenience.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

User is using a homemade topical treatment with .015% finasteride, 5% minoxidil, and microneedling at .75mm depth. They also use 2% ketoconazole shampoo, various oils, and are considering increasing finasteride concentration due to mixed results.

A user shared their 5-month hair transplant progress, having undergone a procedure with 4100 grafts at MedBlue in Istanbul for $3,600. They started taking oral minoxidil and finasteride daily after the transplant and use topical minoxidil with microneedling every two weeks, reporting positive results and no unwanted hair growth.

The user shared a 5-month update on using finasteride, minoxidil, and ketoconazole shampoo for diffuse thinning, along with supplements like B-Vitamins, D-Vitamins, Iron, and Beta carotene. They noted improvement in hair condition and encouraged others to check previous posts for more information.

Follistatin, known for inhibiting myostatin and promoting muscle growth in mice, is being discussed as a potential treatment for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation discusses various hair care techniques and products for improving hair appearance, including hair drying, derma rolling, salt water spray, caffeine shampoo, and styling products like hairspray and matte creams. Users also share experiences with minoxidil, noting its effects on hair texture and volume.

The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.

User shared progress pictures after 5 months using 5 mg oral minoxidil, a topical formula with 8% minoxidil, 0.1% finasteride, and 0.01% tretinoin, and a 1.5 mm Dermapen every other week. The conversation discusses the effectiveness of this regimen for hair loss.

The user shared progress pictures after 5 months of using 1mg finasteride, weekly 1.5mm microneedling, and daily 2mg copper peptide injections. They discussed their hair loss treatment and results.

A 33-year-old male shares his 5-month progress using 1 mg finasteride and 2.5 mg minoxidil daily, along with hair supplements and a serum containing Redensyl, Anagain, Capixyl, and Procapil. He reports thickening of existing hair and new hair growth without side effects, despite experiencing some shedding due to weight loss.

The user is seeking feedback on their hair transplant progress after 5 months, using finasteride, minoxidil, and red light therapy. They are considering a second hair transplant for the crown area.

A 36-year-old shared a 5-month update on their hair transplant of 3153 grafts, expressing satisfaction with the progress while using finasteride and minoxidil for over 13 years. The user noted uneven growth between the right and left sides and sought advice on whether this is typical at this stage.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The user has been using Hims spray with Minoxidil and Finasteride for 5 months, along with derma rolling and ketoconazole shampoo, and is seeing slight hair regrowth. They are advised to continue the treatment and consider a hair transplant in the future.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

The user reports significant hair regrowth using finasteride, topical minoxidil, and dermarolling twice a week, despite poor photo quality. Another user shares their experience with oral minoxidil and finasteride, noting ongoing shedding and considering additional treatments.

The user is using Minoxidil, vitamin D, zinc, biotin, collagen, and micro-needling for hair regrowth. Some users suggest biotin and collagen are ineffective and emphasize the need for a DHT blocker for lasting results.

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

The conversation discusses the potential of Sanguisorba Officinalis Root Extract as a treatment for hair loss by inhibiting FGF-5. The user also mentions the product évolis, which is based on this extract but is only available in the US and Australia.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

Osteopontin, a protein involved in hair growth on moles, may help with hair loss. However, it is also linked to Alzheimer's, cancer, and bone development, so caution is advised.

Dutasteride is more effective than finasteride for hair loss, especially at the crown and midscalp, but both have similar side-effect profiles with low incidence of sexual adverse events. Improvement is measured visually, and significant results may take over 12 months to appear.